
Part 2 (Dose Expansion)
RP2D: Dose B
up to approximately 40 subjects at each RP2D
Part 1 (Dose Escalation)
Dose B
~6 subjects
Study Evaluation Team (SET) will recommend dose escalation after review of available data; more than 2 doses may be examined in Part 1
Dose A
~3 subjects
Screening (Within 28 days)
Study Duration
Abbreviations: RP2D=recommended Phase 2 dose.

FIG. 1


Response Rates[a]
Response rates, %
100
90
80
70
60
50
40
30
20
10
0
4.8%
14.3%
47.6%
9.5%
PR
VGPR
CR
sCR
Dara + Tal[b]
(n=21)

FIG. 2



FIG. 3


Tal + Dara (n=4)a
CD38+/CD8 (fraction)
0.3
0.2
0.1
0.0
C3D1
C3D8
C3D15
C4D1
C4D8
C4D15
C5D1
C5D8
C5D15
C6D1
C6D8
C6D15
C7D1
C7D8
C7D15
C8D1
C8D8
C8D15
C9D1
C9D8
C9D15
C10D1
C10D8
C10D15
C11D1
C11D8
C11D15
C12D1
C12D8
C12D15
Dara
Talb
Talb
Dara
Tal +
Dara
Tal +
Dara
Tal +
Dara

FIG. 4


CD4
CD8
100013
Log10 (Abs #x106^)
1000
100
10
1
C1D1
C1D2
C1D3
C1D4
C1D5
C1D6
C1D8
C1D9
C1D10
C1D15
C1D16
C1D17

FIG. 5


100013
100013 %CD25-CD4
100013 %CD25-CD8
%CD25 positive
0
10
20
30
40
50
C1D1
C1D2
C1D3
C1D4
C1D5
C1D6
C1D8
C1D9
C1D10
C1D15
C1D16
C1D17

FIG. 6


Interferon Gamma (ng/L)
Dara 1800 mg + Tal 10/60 then 400 µg/kg
Value
100
90
80
70
60
50
40
30
20
10
0
C1D1_PRE
C1D2_PRE
C1D3_0H
C1D4_PRE
C1D4_24H
C1D6_72H
C1D8_PRE
C1D9_PRE
C1D10_24H
C1D15_PRE
C1D16_24H
C1D17
C1D21_PRE

FIG. 7A


Tumor Necrosis Factor (ng/L)
Dara 1800mg + Tal 10/60 then 400 µg/kg QW SC
Value
14
13
12
11
10
9
8
7
6
5
4
3
2
1
C1D1_PRE
C1D2_PRE
C1D3_0H
C1D4_PRE
C1D4_24H
C1D8_72H
C1D8_PRE
C1D9_PRE
C1D10_24H
C1D15_PRE
C1D16_24H
C1D17
C1D21_PRE

FIG. 7B


Interleukin 6 (ng/L)
Dara 1800 mg + Tal 10/60 then 400 µg/kg QW SC
Value
700
650
600
550
500
450
400
350
300
250
200
150
100
50
0
C1D1_PRE
C1D2_PRE
C1D3_0H
C1D4_PRE
C1D4_24H
C1D6_72H
C1D8_PRE
C1D9_PRE
C1D10_24H
C1D15_PRE
C1D16_24H
C1D17
C1D21_PRE

FIG. 7C


Interleukin 8 (ng/L)
Dara 1800 mg + Tal 10/60 then 400 µg/kg QW SC
Value
100
90
80
70
60
50
40
30
20
10
C1D1_PRE
C1D2_PRE
C1D3_0H
C1D4_PRE
C1D4_24H
C1D6_72H
C1D8_PRE
C1D9_PRE
C1D10_24H
C1D15_PRE
C1D16_24H
C1D17
C1D21_PRE

FIG. 7D


Talquetamab + Daratumumab
Dose Level (µg/kg)
400 TR+
400
400 TR+
400 TR+
400
400 CD38E
400 CD38RE
800 TR+
800 TR
800 TR
800 TR+
800 TR+
800 CD38E
400 TR
400 CD38RE
400
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Months
Response: sCR CR VGPR PR MR SD PD
On Treatment as of September 7, 2021
End of treatment status: D/C - AE D/C - Other Death
Intra-subject dose reduction: 135

FIG. 8